Department: Biochemistry and Molecular Biology

Research Unit: Instituto de Biotecnología y Salud (IDiBE)

Web page: 

https://www.umh.es/contenido/Estudios/:persona_5632/datos_es.html

https://idibe.umh.es/dra-asia-fernandez-carvajal/

Research Fields:

-Sensory neurobiology with a focus on molecular and cellular mechanisms of pain transduction.

-Discovery and development of anti-nociceptive drugs.

-Structure-function studies on ion channels.

Representative Publications:

• Alarcón-Alarcón, D., Cabañero, D., de Andrés-López, J., Nikolaeva-Koleva, N, Giorgi S., Fernández-Ballester, G., Fernández-Carvajal, A., Ferrer-Montiel, A. (2022) TRPM8 contributes to sex dimorphism by promoting recovery of normal sensitivity in a mouse model of chronic migraine. Nature communication. 13(1):6304
• Angeli, A.; Micheli, L.; Carta, F.; Ferraroni, M.; Pirali, T.; Fernández-Carvajal, A.; Ferrer-Montiel, A.; Di Cesare Mannlli, L; Ghelardini, C.; Supuran, C. T. (2023). First in Class Dual Hybrid Carbonic Anhydrase Inhibitors and Transient Receptor Potential Vanilloid 1 Agonists Revert Oxaliplatin-Induced Neuropathy. Journal of Medicinal Chemistry. 66(2):1616-1633.
• Lamberti A, Serafini M, Aprile S, Bhela IP, Goutsiou G, Pessolano E, Fernandez-Ballester G, Ferrer-Montiel A, Di Martino RMC, Fernandez-Carvajal A, Pirali T. (2024) The multicomponent Passerini reaction as a means of accessing diversity in structure, activity and properties: soft and hard vanilloid/cannabinoid modulators. J.Med.Chemistry. 279, 116845
• Villalba E., De la Torre-Martínez R., Fernández-Carvajal A., Ferrer-Montiel A. (2025) Oxaliplatin reversibly and differentially affects electrogenic activity of small IB4(+) of male and female rat sensory neurons. Biomedicine & Pharmacotherapy. 183, 117849.
• Cabañero D, Carter E.P, González-Cano R, J. Cobos E, Fernández-Carvajal A, Ferrer-Montiel A. (2025) Cold Receptor TRPM8 as a target for Migraine-associated Pain and Affective Comorbidities. Journal of Headache and Pain. 26(1):146-154.

Patents and Available Technologies:

1. Fernández-Carvajal A, García-Martínez C, Belmonte C, Van Den Nest W, Carreño C., Ferrer-Montiel A. Compounds which can block the responses to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same. ES2195787 B1 (granted on 01/06/2005); WO03/097670; EP1506970 A1; US7183430 B2 (granted on 27/02/2003); AU2003/231331; CA2486342 A1; JP2006/502975; MX PA/a/04011502
2. Belmonte Martínez C., Gallar Martínez J., Ferrer Montiel A., Fernández Carvajal A., Viana de la Iglesia, F. Composición farmacéutica para el tratamiento de la epifora. PCT/ES02011/070627 (granted on 20/03/2014) WO2012/032209 A2EP2614860A2, EP2614860A4, US20130245231, WO2012032209A3
3. González Muñoz R., Pérez de Vega MJ, Bonache M.A., Ferrer Montiel A, Fernández Carvajal A, de la Torre R. Compuestos heterocíclicos como antagonistas de canales TRPM8 y sus usos. PCT/ES2016/070483 (granted on 29/06/2016), WO2017005950 A1(granted on 12/01/2017)
4. Devesa I., Genazzani A., Pirali T., Fernández Carvajal A., Ferrer Montiel A. TRPV1 modulator compounds. EP17382266.9; WO2018206742A1 (granted on 15/11/2018).
5. Ferrer Montiel A., Fernández Carvajal A., Belmonte Martínez C., Gallar Martínez J., de la Torre R., Genazzani A., Giancesare T., Mercalli V. Compuestos Agonistas del receptor TRPM8 y sus aplicaciones. PCT/ES2017/070026 (granted on 09/05/2018)

Company agreements:

• AVIZOREX PHARMA SL
• ANTALGENICS, SL
• ALODIA FARMACEUTICA SL